n WHITE PLAINS, NYThe Leukemia & Lymphoma Society
has joined in a collaborative partnership with Novartis to educate the public
about imatinib mesylate (Gleevec, also known as STI-571), Novartis’ new oral
medication approved by the FDA for patients with
Philadelphia-chromosome-positive chronic myelogenous leukemia (CML) who have
failed interferon therapy.
The Society’s Information Resource Center (IRC) can be
reached directly by calling 1-800-955-4572 from 9 am to 6 pm Eastern Standard
Time, or via email at firstname.lastname@example.org.
IRC staff can provide callers with information on CML, imatinib,
and the vast array of free patient services programs available nationwide
through the Society’s 58 chapters, designed to help patients cope with living
For Medicare and other patients eligible for treatment with
imatinib who are concerned about the cost of the drug, the IRC staff has
information about the Novartis Patient Assistance Program (PAP), which will
help patients assess their own funding resources to determine their eligibility
for reimbursement for the cost of the drug.
In selected cases in which sufficient funding is not available,
the Novartis PAP will help patients to obtain the drug who might not otherwise
be able to do so. For information on Novartis PAP, call 1-877-GLEEVEC